Below are the transcripts from the Q2 earnings call. This transcript is brought to you by Benzinga APIs. For real-time access ...

Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically ...

Today, several major companies are expected to report earnings: Inovio Pharmaceuticals (INO), Altimmune (ALT), Sea (SE), ...

Reports Q2 revenue $5,000 vs $5,000 last year. “Pemvidutide demonstrated rapid and robust MASH effects, meaningful weight loss and impressive ...

Analysts estimate that Altimmune will report an earnings per share (EPS) of $-0.32. Anticipation surrounds Altimmune's ...

Appointment recognizes Mr. Durso’s extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent ...

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers ...

Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors ...

Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options If you suffered purchased or acquired securities in Altimmune between August 10, 2023 and ...

Altimmune Inc. (NASDAQ: ALT) is completing a Phase 2 clinical trial of pemvidutide, an anti-obesity drug that appears to be able to bring important benefits to weight loss.

Altimmune Inc. ALT shares rallied more than 40% in the extended session Thursday after the clinical-stage biopharma company said 391 people enrolled in a trial of its obesity drug pemvidutide lost ...

Altimmune has gone all-in on pemvidutide, a GLP-1/glucagon dual receptor agonist, and has the potential to secure blockbuster status, but they run the risk of regulatory failure.